Array
(
    [id] => chatcmpl-AipYaTA71DDrG9PYgKjmFVlEc9Za2
    [object] => chat.completion
    [created] => 1735247980
    [model] => gpt-4o-mini-2024-07-18
    [choices] => Array
        (
            [0] => Array
                (
                    [index] => 0
                    [message] => Array
                        (
                            [role] => assistant
                            [content] => * Patients with advanced malignant melanoma have a low 5-year survival rate of 15-20% after metastasis, prompting research into why many initially respond to MAP kinase pathway inhibitors (MAPKi) but later relapse. *! 
* A genetic screen identified the loss of proteins NF1 and CUL3 as key factors driving resistance to the MAPKi drug vemurafenib; NF1 is already known to contribute to resistance, while CUL3's role was less clear. *! 
* The study revealed that loss of CUL3 enhances RAC1 activity and MEK phosphorylation, and using a Src family inhibitor (saracatinib) can counteract this resistance mechanism, suggesting that targeting Src may help overcome MAPKi resistance linked to
                            [refusal] => 
                        )

                    [logprobs] => 
                    [finish_reason] => length
                )

        )

    [usage] => Array
        (
            [prompt_tokens] => 405
            [completion_tokens] => 150
            [total_tokens] => 555
            [prompt_tokens_details] => Array
                (
                    [cached_tokens] => 0
                    [audio_tokens] => 0
                )

            [completion_tokens_details] => Array
                (
                    [reasoning_tokens] => 0
                    [audio_tokens] => 0
                    [accepted_prediction_tokens] => 0
                    [rejected_prediction_tokens] => 0
                )

        )

    [system_fingerprint] => fp_0aa8d3e20b
)